Zentalis Pharmaceuticals, Inc.
ZNTL
Positions held
Your positionsZNTL isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $246.29M | Enterprise value | $42.98M | Trailing P/E | — | Forward P/E | -1.38 |
| PEG | — | Price / book | 1.25 | Beta | 1.94 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -66.7% | ROA | -33.2% | Debt / equity | 0.26 |
| Current ratio | 4.82 | Free cash flow | -$79.45M | Analyst recommendation | buy | Mean target | $7.33 |
| 52w high | $6.95 | 52w low | $1.21 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$42.3M | -$35.4M | -$35.2M | -$26.7M | -$26.9M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$44.4M | -$37.9M | -$37.4M | -$33.7M | -$36.1M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $67.4M | $0.0M | $0.0M | — |
| Op margin | — | -278.0% | — | — | — |
| Net income | -$137M | -$166M | -$292M | -$237M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$145M | -$187M | -$254M | -$227M | — |
Headlines — positive tone
• [OK · fundamentals] Zentalis Pharmaceuticals Shares Rise After Leerink Upgrade
News
2026-10-05 · Zentalis Pharmaceuticals Shares Rise After Leerink Upgrade
2026-10-05 · Zentalis Pharmaceuticals Shares Rise After Leerink Assumes Coverage With Outperform Rating
2026-10-05 · Leerink Upgrades Zentalis Pharmaceuticals to Outperform From Market Perform, Price Target is $8
2026-10-01 · Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-09-16 · William Blair Initiates Zentalis Pharmaceuticals at Outperform
2026-09-02 · Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
2026-09-01 · Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-08-20 · Zentalis Pharmaceuticals Insider Bought Shares Worth $15,172,500, According to a Recent SEC Filing
2026-08-17 · Zentalis Pharmaceuticals Closes Offering of Common Shares
2026-08-14 · Sector Update: Healthcare Stocks Decline Late Afternoon
2026-08-14 · Sector Update: Healthcare
Price (daily)
Full chart · RSI · MACD · patterns